<code id='2B4697F76F'></code><style id='2B4697F76F'></style>
    • <acronym id='2B4697F76F'></acronym>
      <center id='2B4697F76F'><center id='2B4697F76F'><tfoot id='2B4697F76F'></tfoot></center><abbr id='2B4697F76F'><dir id='2B4697F76F'><tfoot id='2B4697F76F'></tfoot><noframes id='2B4697F76F'>

    • <optgroup id='2B4697F76F'><strike id='2B4697F76F'><sup id='2B4697F76F'></sup></strike><code id='2B4697F76F'></code></optgroup>
        1. <b id='2B4697F76F'><label id='2B4697F76F'><select id='2B4697F76F'><dt id='2B4697F76F'><span id='2B4697F76F'></span></dt></select></label></b><u id='2B4697F76F'></u>
          <i id='2B4697F76F'><strike id='2B4697F76F'><tt id='2B4697F76F'><pre id='2B4697F76F'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:398
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          See how much Covid
          See how much Covid

          NewYork-PresbyterianHospitalreceived$631millionfromtheCovid-19ProviderReliefFund.CindyOrd/GettyImage

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

          ChrisBoshoff,farright,speakingatapanelwith,fromleft,MatthewHerperofSTAT,KenKeller,LeviGarraway,andSu